STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] CeriBell, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Ceribell, Inc. (CBLL) reporting person Raymond Woo, Chief Technology Officer, disclosed an open-market sale of 687 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the transaction he beneficially owned 147,704 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025. No derivative transactions were reported.

Positive
  • Disclosure complied with Section 16 requirements, including transaction details and attorney-in-fact signature
  • Post-transaction holdings remain substantial at 147,704 shares, showing continued insider ownership
Negative
  • None.

Insights

TL;DR: Insider sold a small quantity of shares; holding remains substantial, suggesting routine liquidity rather than strategic change.

The sale of 687 shares at $11.58 is modest relative to the remaining 147,704 shares reported, indicating this transaction is likely a limited liquidity event by the CTO rather than a significant shift in ownership. No options or other derivative activity were reported, and the filing shows a routine Section 16 disclosure. Impact is neutral absent additional context on timing or pattern of sales.

TL;DR: Transaction is properly disclosed under Section 16; documentation shows attorney-in-fact signature and an ordinary open-market sale.

Form 4 includes the required information: reporting person, relationship (CTO), transaction date, price, number sold, and post-transaction holdings. The presence of an attorney-in-fact signature indicates authorized filing. There are no indications of rule 10b5-1 plan use noted on the form. Governance implications appear routine and compliant based on the provided data.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Woo Raymond

(Last) (First) (Middle)
C/O CERIBELL, INC.
360 N. PASTORIA AVENUE

(Street)
SUNNYVALE CA 94085

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Ceribell, Inc. [ CBLL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technology Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/25/2025 F 687 D $11.58 147,704 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Louisa Daniels, Attorney-in-Fact for Raymond Woo 08/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Raymond Woo (CTO) report on Form 4 for CBLL?

He reported an open-market sale of 687 shares on 08/25/2025 at $11.58 per share and beneficial ownership of 147,704 shares after the sale.

When was the Form 4 for CBLL filed and signed?

The transaction date is 08/25/2025 and the form bears an attorney-in-fact signature dated 08/27/2025.

Did the Form 4 report any derivative transactions for CBLL?

No. Table II shows no derivative securities were reported in this filing.

Does the filing indicate use of a 10b5-1 trading plan?

The form does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan.
CeriBell, Inc.

NASDAQ:CBLL

CBLL Rankings

CBLL Latest News

CBLL Latest SEC Filings

CBLL Stock Data

428.83M
28.79M
10.43%
84.44%
3.61%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SUNNYVALE